<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7338588\results\search\disease\results.xml">
  <result pre="Immunology: Mini Review Deciphering the Role of Host Genetics in" exact="Susceptibility to" post="Severe COVID-19 Carter-TimofteMadalina Elena12JÃ¸rgensenSofie Eg12FreytagMette Ratzer12ThomsenMichelle MÃ¸lgaard12Brinck AndersenNanna-Sophie12Al-MousawiAli12HaitAlon Schneider12MogensenTrine"/>
  <result pre="Review Deciphering the Role of Host Genetics in Susceptibility to" exact="Severe" post="COVID-19 Carter-TimofteMadalina Elena12JÃ¸rgensenSofie Eg12FreytagMette Ratzer12ThomsenMichelle MÃ¸lgaard12Brinck AndersenNanna-Sophie12Al-MousawiAli12HaitAlon Schneider12MogensenTrine H.123*[],"/>
  <result pre="AndersenNanna-Sophie12Al-MousawiAli12HaitAlon Schneider12MogensenTrine H.123*[], 1Department of Biomedicine, Aarhus UniversityAarhusDenmark[], 2Department of" exact="Infectious" post="Diseases, Aarhus University Hospital (AUH)AarhusDenmark[], 3Department of Clinical MedicineAarhusDenmark"/>
  <result pre="*Correspondence: Trine H. Mogensen trine.mogensen@biomed.au.dk This article was submitted to" exact="Primary" post="Immunodeficiencies, a section of the journal Frontiers in Immunology"/>
  <result pre="disease-19 (COVID-19) describes a set of symptoms that develop following" exact="infection" post="by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)."/>
  <result pre="set of symptoms that develop following infection by the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2). Whilst COVID-19 disease is"/>
  <result pre="of symptoms that develop following infection by the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2). Whilst COVID-19 disease is most"/>
  <result pre="symptoms that develop following infection by the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2). Whilst COVID-19 disease is most serious"/>
  <result pre="the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Whilst COVID-19" exact="disease" post="is most serious in patients with significant co-morbidities, the"/>
  <result pre="significant co-morbidities, the reason for healthy individuals succumbing to fulminant" exact="infection" post="is largely unexplained. In this review, we discuss the"/>
  <result pre="genetic effect on host immune response pathways leading to increased" exact="susceptibility to" post="SARS-CoV-2 infection. Understanding these pathways may help not only"/>
  <result pre="infection. Understanding these pathways may help not only in unraveling" exact="disease" post="pathogenesis, but also in suggesting targets for therapy and"/>
  <result pre="similar pandemics. SARS-coronavirus 2 host immune defenses immunopathology innate immunity" exact="primary" post="immunodeficiency whole exome sequencing Funding Det Frie ForskningsrÃ¥d10.13039/501100004836 fig-count:"/>
  <result pre="pandemics. SARS-coronavirus 2 host immune defenses immunopathology innate immunity primary" exact="immunodeficiency" post="whole exome sequencing Funding Det Frie ForskningsrÃ¥d10.13039/501100004836 fig-count: table-count:"/>
  <result pre="page-count: word-count: Introduction In late December 2019, several cases of" exact="acute" post="respiratory distress syndrome (ARDS) were reported across several provinces"/>
  <result pre="word-count: Introduction In late December 2019, several cases of acute" exact="respiratory" post="distress syndrome (ARDS) were reported across several provinces in"/>
  <result pre="In late December 2019, several cases of acute respiratory distress" exact="syndrome" post="(ARDS) were reported across several provinces in China, and"/>
  <result pre="zoonotic coronaviruses are known to have the capability to cause" exact="respiratory" post="disease in humans. The human coronaviruses (HCoV) 229E, NL63,"/>
  <result pre="coronaviruses are known to have the capability to cause respiratory" exact="disease" post="in humans. The human coronaviruses (HCoV) 229E, NL63, OC43,"/>
  <result pre="OC43, and HKU1 are identified as weakly pathogenic, causing mild" exact="upper" post="respiratory disease (3). However, during the last two decades,"/>
  <result pre="and HKU1 are identified as weakly pathogenic, causing mild upper" exact="respiratory" post="disease (3). However, during the last two decades, public"/>
  <result pre="HKU1 are identified as weakly pathogenic, causing mild upper respiratory" exact="disease" post="(3). However, during the last two decades, public health"/>
  <result pre="has been threatened by two highly pathogenic coronaviruses, including severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) in 2002, and Middle-East respiratory"/>
  <result pre="been threatened by two highly pathogenic coronaviruses, including severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) in 2002, and Middle-East respiratory coronavirus,"/>
  <result pre="threatened by two highly pathogenic coronaviruses, including severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) in 2002, and Middle-East respiratory coronavirus, (MERS-CoV)"/>
  <result pre="severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002, and Middle-East" exact="respiratory" post="coronavirus, (MERS-CoV) in 2012 (4). The 2019/20 outbreak was"/>
  <result pre="may provide some explanation for failure to control SARS-CoV-2 infection." exact="Primary" post="immunodeficiencies (PIDs) are a group of genetically determined diseases"/>
  <result pre="evidence that the extreme variability in the clinical outcome of" exact="infections" post="can often be influenced by the germ line genetics"/>
  <result pre="of immunity predispose to a narrow or broad range of" exact="viral" post="infections (6, 9, 10). Examples include herpes simplex virus"/>
  <result pre="immunity predispose to a narrow or broad range of viral" exact="infections" post="(6, 9, 10). Examples include herpes simplex virus encephalitis"/>
  <result pre="broad range of viral infections (6, 9, 10). Examples include" exact="herpes" post="simplex virus encephalitis and defects in the TLR3 pathway"/>
  <result pre="viral infections (6, 9, 10). Examples include herpes simplex virus" exact="encephalitis" post="and defects in the TLR3 pathway and RNA metabolism"/>
  <result pre="IRF9 (17), TLR3 (18), GATA2 (19), and RIG-I (20), rhinovirus" exact="infection" post="and MDA5 (21), papillomaviruses and mutations in EVER1/2 (22),"/>
  <result pre="(24), XIAP (25), ITK (26), and MAGT1 (27), fatal CMV" exact="infection" post="in NOS2 deficiency (28), and finally disseminated infection with"/>
  <result pre="ITK (26), and MAGT1 (27), fatal CMV infection in NOS2" exact="deficiency" post="(28), and finally disseminated infection with measles vaccine strain"/>
  <result pre="fatal CMV infection in NOS2 deficiency (28), and finally disseminated" exact="infection" post="with measles vaccine strain virus in IFNAR and STAT2"/>
  <result pre="infection in NOS2 deficiency (28), and finally disseminated infection with" exact="measles" post="vaccine strain virus in IFNAR and STAT2 deficiency (29,"/>
  <result pre="infection with measles vaccine strain virus in IFNAR and STAT2" exact="deficiency" post="(29, 30). In this review, we aim to discuss"/>
  <result pre="symptoms, whereas others become critically ill requiring intensive care and" exact="respiratory" post="ventilation (31â€&quot;33). The frequency of asymptomatic infections is yet"/>
  <result pre="intensive care and respiratory ventilation (31â€&quot;33). The frequency of asymptomatic" exact="infections" post="is yet to be determined and the differentiation between"/>
  <result pre="ICU, a CFR of 49â€&quot;61% was reported (36). Whilst severe" exact="disease" post="outcomes have been reported in otherwise healthy individuals of"/>
  <result pre="risk factors are recognized that lead to a more critical" exact="disease" post="course; these include old age, hypertension, diabetes, obesity, cardiovascular,"/>
  <result pre="these include old age, hypertension, diabetes, obesity, cardiovascular, pulmonary, and" exact="cerebrovascular disease" post="(37). COVID-19 initially presents with non-specific signs and symptoms"/>
  <result pre="include old age, hypertension, diabetes, obesity, cardiovascular, pulmonary, and cerebrovascular" exact="disease" post="(37). COVID-19 initially presents with non-specific signs and symptoms"/>
  <result pre="(37). COVID-19 initially presents with non-specific signs and symptoms of" exact="upper" post="airway viral infection characterized by fever, fatigue, cough, and"/>
  <result pre="initially presents with non-specific signs and symptoms of upper airway" exact="viral infection" post="characterized by fever, fatigue, cough, and dyspnoea, as well"/>
  <result pre="presents with non-specific signs and symptoms of upper airway viral" exact="infection" post="characterized by fever, fatigue, cough, and dyspnoea, as well"/>
  <result pre="as anorexia, myalgia, and productive sputum, which can develop to" exact="pneumonia" post="(32, 38). Intriguingly, patients are increasingly reporting anosmia and"/>
  <result pre="has subsequently been confirmed by several reports of central and" exact="peripheral" post="nervous system manifestations, with meningitis, encephalitis, myelitis, and Guillain-Barre"/>
  <result pre="and peripheral nervous system manifestations, with meningitis, encephalitis, myelitis, and" exact="Guillain-Barre syndrome" post="presenting as components of severe COVID-19 (40, 41). In"/>
  <result pre="peripheral nervous system manifestations, with meningitis, encephalitis, myelitis, and Guillain-Barre" exact="syndrome" post="presenting as components of severe COVID-19 (40, 41). In"/>
  <result pre="as components of severe COVID-19 (40, 41). In this context," exact="respiratory" post="failure has been hypothesized to be partly neurogenic in"/>
  <result pre="to be partly neurogenic in origin and possibly resulting from" exact="viral" post="invasion of cranial nerve I into brainstem respiratory centers"/>
  <result pre="in origin and possibly resulting from viral invasion of cranial" exact="nerve" post="I into brainstem respiratory centers (41). Gastrointestinal symptoms, particularly"/>
  <result pre="resulting from viral invasion of cranial nerve I into brainstem" exact="respiratory" post="centers (41). Gastrointestinal symptoms, particularly nausea, vomiting, and diarrhea,"/>
  <result pre="are commonly described (42). In the most critical cases, widespread" exact="lung inflammation" post="can lead to acute respiratory distress syndrome (ARDS), which"/>
  <result pre="the most critical cases, widespread lung inflammation can lead to" exact="acute" post="respiratory distress syndrome (ARDS), which often necessitates mechanical ventilation"/>
  <result pre="most critical cases, widespread lung inflammation can lead to acute" exact="respiratory" post="distress syndrome (ARDS), which often necessitates mechanical ventilation or"/>
  <result pre="cases, widespread lung inflammation can lead to acute respiratory distress" exact="syndrome" post="(ARDS), which often necessitates mechanical ventilation or extracorporeal membrane"/>
  <result pre="necessitates mechanical ventilation or extracorporeal membrane oxygenation (ECMO) to prevent" exact="total" post="respiratory failure (43). Recent studies have demonstrated an extensive"/>
  <result pre="mechanical ventilation or extracorporeal membrane oxygenation (ECMO) to prevent total" exact="respiratory" post="failure (43). Recent studies have demonstrated an extensive tendency"/>
  <result pre="have demonstrated an extensive tendency for coagulopathy, thrombosis, micro-thrombosis, and" exact="disseminated intravascular coagulation" post="during severe COVID-19 (44, 45) which is reflected in"/>
  <result pre="which is reflected in elevated fibrin and D-dimer levels during" exact="disease" post="(46). Furthermore, a significant fraction of deceased ICU patients"/>
  <result pre="(46). Furthermore, a significant fraction of deceased ICU patients have" exact="pulmonary thrombosis" post="or deep vein thrombosis as revealed by autopsy results"/>
  <result pre="Furthermore, a significant fraction of deceased ICU patients have pulmonary" exact="thrombosis" post="or deep vein thrombosis as revealed by autopsy results"/>
  <result pre="significant fraction of deceased ICU patients have pulmonary thrombosis or" exact="deep vein thrombosis" post="as revealed by autopsy results (47). Several clinical and"/>
  <result pre="of deceased ICU patients have pulmonary thrombosis or deep vein" exact="thrombosis" post="as revealed by autopsy results (47). Several clinical and"/>
  <result pre="immune activation may represent an important strategy in treating this" exact="disease" post="and decreasing the high mortality (51, 52). Finally, there"/>
  <result pre="with a clinical picture of auto-inflammation and vasculitis, diagnosed as" exact="atypical" post="Kawasaki's disease (53), a rare disease entity causing systemic"/>
  <result pre="a clinical picture of auto-inflammation and vasculitis, diagnosed as atypical" exact="Kawasaki's disease" post="(53), a rare disease entity causing systemic inflammation, fever,"/>
  <result pre="clinical picture of auto-inflammation and vasculitis, diagnosed as atypical Kawasaki's" exact="disease" post="(53), a rare disease entity causing systemic inflammation, fever,"/>
  <result pre="and vasculitis, diagnosed as atypical Kawasaki's disease (53), a rare" exact="disease" post="entity causing systemic inflammation, fever, and vasculitis with a"/>
  <result pre="as atypical Kawasaki's disease (53), a rare disease entity causing" exact="systemic" post="inflammation, fever, and vasculitis with a risk of developing"/>
  <result pre="(53), a rare disease entity causing systemic inflammation, fever, and" exact="vasculitis" post="with a risk of developing aneurisms. This inflammatory condition"/>
  <result pre="developing aneurisms. This inflammatory condition associated with a previous SARS-CoV-2" exact="infection" post="has been named Pediatric Multisystem Inflammatory Syndrome temporally associated"/>
  <result pre="condition associated with a previous SARS-CoV-2 infection has been named" exact="Pediatric" post="Multisystem Inflammatory Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) (54)."/>
  <result pre="associated with a previous SARS-CoV-2 infection has been named Pediatric" exact="Multisystem" post="Inflammatory Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) (54). SARS-CoV-2"/>
  <result pre="with a previous SARS-CoV-2 infection has been named Pediatric Multisystem" exact="Inflammatory" post="Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) (54). SARS-CoV-2 Coronaviruses"/>
  <result pre="a previous SARS-CoV-2 infection has been named Pediatric Multisystem Inflammatory" exact="Syndrome" post="temporally associated with SARS-CoV-2 (PIMS-TS) (54). SARS-CoV-2 Coronaviruses are"/>
  <result pre="suggesting that SARS-CoV-2 originates from this bat species (58). An" exact="intermediate" post="animal host between horseshoe bats and humans, as well"/>
  <result pre="(59). However, the most prevalent hypothesis is that the virus" exact="acquired" post="one or several mutations allowing it to cross species"/>
  <result pre="host cell membrane (63, 64). Furthermore, overexpression of ACE2 enhances" exact="disease" post="severity in mice upon SARS-CoV infection, indicating the importance"/>
  <result pre="SARS-CoV infection, indicating the importance of this receptor in facilitating" exact="viral" post="entry (65). Several studies have shown that the S"/>
  <result pre="SARS-CoV S protein (66â€&quot;69). Furthermore, ACE2 is highly expressed by" exact="type II" post="alveolar epithelial cells (70, 71) which correlates with the"/>
  <result pre="(66â€&quot;69). Furthermore, ACE2 is highly expressed by type II alveolar" exact="epithelial" post="cells (70, 71) which correlates with the pulmonary symptoms"/>
  <result pre="II alveolar epithelial cells (70, 71) which correlates with the" exact="pulmonary" post="symptoms of COVID-19 (32). However, ACE2 is also highly"/>
  <result pre="symptoms and complications that SARS-CoV-2 patients exhibit, such as diarrhea," exact="kidney failure" post="and cardiac injury (32, 73). Innate Immune Responses to"/>
  <result pre="defense against a wide range of pathogens, particularly viruses. Importantly," exact="viral infection" post="induces type I interferons (IFN) (IFNÎ±/Î²) and type III"/>
  <result pre="against a wide range of pathogens, particularly viruses. Importantly, viral" exact="infection" post="induces type I interferons (IFN) (IFNÎ±/Î²) and type III"/>
  <result pre="wide range of pathogens, particularly viruses. Importantly, viral infection induces" exact="type I" post="interferons (IFN) (IFNÎ±/Î²) and type III IFNs (IFN-Î»), which"/>
  <result pre="Importantly, viral infection induces type I interferons (IFN) (IFNÎ±/Î²) and" exact="type III" post="IFNs (IFN-Î»), which activate hundreds of antiviral proteins as"/>
  <result pre="inducible gene I (RIG-I)-like receptors (RLRs). These receptors recognize several" exact="viral" post="components, which induce downstream signaling and result in production"/>
  <result pre="which induce downstream signaling and result in production of antiviral" exact="type I" post="and III IFNs as well as proinflammatory cytokines through"/>
  <result pre="Figure 1 Induction of interferons (IFN) and signaling by the" exact="type I" post="and III IFN receptors. The presence of microbial or"/>
  <result pre="mitochondrial antiviral signaling protein (MAVS), TIR-domain-containing adapter-inducing interferon-Î² (TRIF), and" exact="Myeloid" post="differentiation primary response (MyD)88 leading to phosphorylation and activation"/>
  <result pre="signaling protein (MAVS), TIR-domain-containing adapter-inducing interferon-Î² (TRIF), and Myeloid differentiation" exact="primary" post="response (MyD)88 leading to phosphorylation and activation of the"/>
  <result pre="expressed at low levels but may be secondarily induced by" exact="Type I" post="IFN. Phosphorylation of IRF3 and IRF7 leads to homodimerization,"/>
  <result pre="and IRF7 leads to homodimerization, nuclear translocation, and expression of" exact="Type I" post="IFNs (IFNÎ± and IFNÎ²) and type III IFNs (IFNÎ»)"/>
  <result pre="and expression of Type I IFNs (IFNÎ± and IFNÎ²) and" exact="type III" post="IFNs (IFNÎ») acting on neighboring cells with type I"/>
  <result pre="and type III IFNs (IFNÎ») acting on neighboring cells with" exact="type I" post="and III IFN receptors, respectively. Type I IFN binds"/>
  <result pre="neighboring cells with type I and III IFN receptors, respectively." exact="Type I" post="IFN binds to IFNÎ±/Î² receptor composed of IRFNAR1 and"/>
  <result pre="binds to IFNÎ±/Î² receptor composed of IRFNAR1 and IFNAR2, whereas" exact="type III" post="IFN binds to the IFNÎ» receptor composed of IFNLR1"/>
  <result pre="activate the adaptor TIR-domain-containing adapter-inducing interferon-Î² (TRIF), whereas myeloid differentiation" exact="primary" post="response 88 (MyD88) is the adaptor used by all"/>
  <result pre="immune signaling pathways that are known to be activated during" exact="viral infection" post="and replication. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"/>
  <result pre="signaling pathways that are known to be activated during viral" exact="infection" post="and replication. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"/>
  <result pre="are known to be activated during viral infection and replication." exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects human cells"/>
  <result pre="known to be activated during viral infection and replication. Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infects human cells through"/>
  <result pre="to be activated during viral infection and replication. Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infects human cells through the"/>
  <result pre="be activated during viral infection and replication. Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infects human cells through the angiotensin-converting"/>
  <result pre="2 (ACE2 receptor) and the cellular serine protease TMPRSS2 for" exact="viral" post="S protein priming. Following cellular entry, the virus RNA"/>
  <result pre="recognized by the retinoic acid inducible receptor (RIG)-I or the" exact="melanoma" post="differentiation-associated protein (MDA)5. Following viral recognition by PRRs, this"/>
  <result pre="inducible receptor (RIG)-I or the melanoma differentiation-associated protein (MDA)5. Following" exact="viral" post="recognition by PRRs, this triggers signaling through IFN regulatory"/>
  <result pre="by extracellular virus through TLR4. Several studies have demonstrated that" exact="infection" post="of Tlr3âˆ’/âˆ’, Tlr4âˆ’/âˆ’, Trifâˆ’/âˆ’, Tramâˆ’/âˆ’, and Myd88âˆ’/âˆ’ mice with"/>
  <result pre="Tlr4âˆ’/âˆ’, Trifâˆ’/âˆ’, Tramâˆ’/âˆ’, and Myd88âˆ’/âˆ’ mice with SARS-CoV causes increased" exact="viral" post="replication, enhanced pathology in the lungs, and increased morbidity"/>
  <result pre="downstream adaptors TRIF and MyD88 (77, 78). Interestingly, following SARS-CoV" exact="infection" post="of Trifâˆ’/âˆ’ mice, the aberrant proinflammatory cytokine and chemokine"/>
  <result pre="were similar to those seen in human patients with poor" exact="disease" post="outcome during SARS-CoV infection (80) or MERS-CoV infection (81)."/>
  <result pre="seen in human patients with poor disease outcome during SARS-CoV" exact="infection" post="(80) or MERS-CoV infection (81). This may suggest that"/>
  <result pre="with poor disease outcome during SARS-CoV infection (80) or MERS-CoV" exact="infection" post="(81). This may suggest that the initial impaired control"/>
  <result pre="(81). This may suggest that the initial impaired control of" exact="viral" post="replication could lead to exaggerated immune responses and enhanced"/>
  <result pre="in humans, since previous studies have failed to report increased" exact="susceptibility to" post="severe viral infection in patients deficient in these molecules"/>
  <result pre="previous studies have failed to report increased susceptibility to severe" exact="viral infection" post="in patients deficient in these molecules (82). This underlines"/>
  <result pre="studies have failed to report increased susceptibility to severe viral" exact="infection" post="in patients deficient in these molecules (82). This underlines"/>
  <result pre="(82). This underlines the value of studying the spectrum of" exact="infections" post="in patients with well-defined immunodeficiencies in natura, revealing important"/>
  <result pre="recognition by TLRs, also recognized by RLRs. The RLRs are" exact="cytosolic" post="RNA sensors, where RIG-I recognizes short dsRNA with 5'"/>
  <result pre="RLRs. The RLRs are cytosolic RNA sensors, where RIG-I recognizes" exact="short" post="dsRNA with 5' triphosphate, and melanoma differentiation-associated protein 5"/>
  <result pre="sensors, where RIG-I recognizes short dsRNA with 5' triphosphate, and" exact="melanoma" post="differentiation-associated protein 5 (MDA5) recognizes long dsRNA. MDA5 is"/>
  <result pre="clearly protective in mice infected with the murine coronavirus mouse" exact="hepatitis" post="virus (MHV) (84), whereas there are only limited reports"/>
  <result pre="coronavirus mouse hepatitis virus (MHV) (84), whereas there are only" exact="limited" post="reports indicating that the other RLRs are important in"/>
  <result pre="the pathogenicity of the virus (86, 87). However, in the" exact="absence of" post="MDA5 or Interferon Induced Protein With Tetratricopeptide Repeats 1"/>
  <result pre="87). However, in the absence of MDA5 or Interferon Induced" exact="Protein" post="With Tetratricopeptide Repeats 1 (IFIT1), the SARS-CoV nsp16 deletion"/>
  <result pre="(IFIT1), the SARS-CoV nsp16 deletion mutant reached similar levels of" exact="viral" post="replication and virulence as wild type SARS-CoV (86, 87),"/>
  <result pre="due to the fact that RIG-I has a preference for" exact="short" post="dsRNA and also because the initial steps of capping"/>
  <result pre="by removing the 5'triphosphate (85). Investigations into the role of" exact="lung inflammation" post="during respiratory infection identified a potential role for excessive"/>
  <result pre="5'triphosphate (85). Investigations into the role of lung inflammation during" exact="respiratory" post="infection identified a potential role for excessive inflammasome activation."/>
  <result pre="(85). Investigations into the role of lung inflammation during respiratory" exact="infection" post="identified a potential role for excessive inflammasome activation. Mice"/>
  <result pre="been deleted by CASP1/11 knock-out displayed less mortality upon influenza" exact="infection" post="compared to wild-type mice (88). Furthermore, inflammation was shown"/>
  <result pre="activation. Given that neutrophilia is a paraclinical indication of COVID-19" exact="disease" post="severity, we might predict that inhibiting this response may"/>
  <result pre="PYD domains-containing protein 3 (NLRP3) inflammasome activation by the SARS-CoV" exact="viral" post="proteins, E, ORF-8b and viroporin 3a (89â€&quot;91). Importantly, coronaviruses"/>
  <result pre="implicated neutrophils and neutrophil extracellular traps (NET) in organ damage," exact="pulmonary" post="pathology, micro-thrombosis, and mortality in COVID-19 (93, 94). NETs"/>
  <result pre="oxidant enzymes that are released by neutrophils to contain microbial" exact="infections" post="but also have the potential to propagate inflammation and"/>
  <result pre="prominent antiviral effectors of the innate immune system, and SARS-CoV" exact="infection" post="is highly susceptible to this potent antiviral substance, as"/>
  <result pre="potent antiviral substance, as shown by the efficient inhibition of" exact="viral" post="replication upon administration of exogenous IFN both in vitro"/>
  <result pre="both in vitro and in vivo (95â€&quot;100). However, only very" exact="limited" post="amounts of IFNs are actually produced during SARS-CoV and"/>
  <result pre="amounts of IFNs are actually produced during SARS-CoV and MERS-CoV" exact="infections" post="(101), and the response seems to be delayed relative"/>
  <result pre="cell IFN and ISG expression compared to influenza A and" exact="respiratory" post="syncytial virus in vitro (103). In support of these"/>
  <result pre="support of these data, a comparative study reported more efficient" exact="viral" post="replication and a reduced type I IFN response in"/>
  <result pre="comparative study reported more efficient viral replication and a reduced" exact="type I" post="IFN response in SARS-CoV-2 infection of ex-vivo human lung"/>
  <result pre="replication and a reduced type I IFN response in SARS-CoV-2" exact="infection" post="of ex-vivo human lung cultures compared to SARS-CoV (104)."/>
  <result pre="T cell responses correlates well with positive outcomes during SARS-CoV" exact="infection" post="(108, 109). Clinical investigations of severe COVID-19 patients consistently"/>
  <result pre="plasma pro-inflammatory cytokines such as Interleukin (IL)-1Î², IL-6, IL-8, and" exact="tumor" post="necrosis factor-Î± (TNF-a) are observed in severe COVID-19 patients,"/>
  <result pre="to be determined. Cytotoxic T cells are important for clearing" exact="respiratory" post="viruses and providing long-term protection; however, the magnitude of"/>
  <result pre="Histological examination of a patient who died from severe SARS-CoV-2" exact="infection" post="identified that whilst the overall peripheral CD4+ and CD8+"/>
  <result pre="died from severe SARS-CoV-2 infection identified that whilst the overall" exact="peripheral" post="CD4+ and CD8+ T cell counts were significantly reduced,"/>
  <result pre="tissue injury (116). Moreover, lung biopsy revealed desquamation of pneumocytes," exact="pulmonary" post="oedema, and hyaline membrane formation, indicative of early-stage ARDS"/>
  <result pre="in SARS-CoV infection, and mild cases of COVID-19 have increased" exact="clonal" post="expansion of CD8+ T cells, compared to severe cases"/>
  <result pre="by immune dysregulation rather than direct pathology induced by high" exact="viral" post="load (111, 118), with a similar picture emerging for"/>
  <result pre="for SARS-CoV-2. A considerable number of studies have demonstrated that" exact="infection" post="with SARS-CoV-2 initiates an antibody response. On average, seroconversion"/>
  <result pre="vs. non-critical COVID-19 patients, possibly reflecting more severe and invasive" exact="infection" post="and thus making it difficult to determine the specific"/>
  <result pre="the association (124, 125) whereas others report no correlation between" exact="disease" post="severity and serum antibody levels (126). Such discrepancies between"/>
  <result pre="area of investigation. Individuals who recovered from SARS-CoV or MERS-CoV" exact="infection" post="displayed high tires of antibodies which waned after 2â€&quot;3"/>
  <result pre="SARS-recovered individuals identified SARS-specific memory T cells 11 years after" exact="infection" post="(129). Finally, the efficacy and longevity of immunity to"/>
  <result pre="low virus mutation rate with mutations randomly spread throughout the" exact="viral" post="genome, suggesting absence of positive selection toward increased virulence"/>
  <result pre="rate with mutations randomly spread throughout the viral genome, suggesting" exact="absence of" post="positive selection toward increased virulence (60). Moreover, previous studies"/>
  <result pre="to lose virulence over time than the opposite (130). Human" exact="Inborn Errors" post="of Immunity Predisposing to Coronavirus Infection Several predisposing factors"/>
  <result pre="opposite (130). Human Inborn Errors of Immunity Predisposing to Coronavirus" exact="Infection" post="Several predisposing factors are known to increase the risk"/>
  <result pre="inborn errors of immunity can alter the course of various" exact="viral" post="infections (131), but in the case of disease progression"/>
  <result pre="errors of immunity can alter the course of various viral" exact="infections" post="(131), but in the case of disease progression in"/>
  <result pre="of various viral infections (131), but in the case of" exact="disease" post="progression in SARS-CoV-2 infection, little is known regarding the"/>
  <result pre="to life-threatening clinical manifestations. It has been proposed that deficient" exact="type I" post="IFN production may undermine the innate immune response during"/>
  <result pre="response during early SARS-CoV infection, resulting in a more severe" exact="disease" post="course (80, 132, 133). Population studies have identified single"/>
  <result pre="(SNPs) in the IFN-inducible genes OAS1 and MX1, associated with" exact="susceptibility to" post="SARS-CoV infection and disease progression (134, 135). Moreover, exogenous"/>
  <result pre="IFN-inducible genes OAS1 and MX1, associated with susceptibility to SARS-CoV" exact="infection" post="and disease progression (134, 135). Moreover, exogenous administration of"/>
  <result pre="OAS1 and MX1, associated with susceptibility to SARS-CoV infection and" exact="disease" post="progression (134, 135). Moreover, exogenous administration of type I"/>
  <result pre="infection and disease progression (134, 135). Moreover, exogenous administration of" exact="type I" post="IFN has been shown to inhibit SARS-CoV replication both"/>
  <result pre="100). Together, these data highlight the importance of an intact" exact="type I" post="IFN pathway in the innate response to SARS-CoV, and"/>
  <result pre="mutations that impair this response may somehow predispose to COVID-19" exact="disease" post="progression. Consequently, it is worth considering that clinical outcome"/>
  <result pre="IRF7, as well as molecules involved in effector function of" exact="type I" post="and III IFN, such as IFNAR1/2 or the janus"/>
  <result pre="has been proposed as an effective therapeutic intervention in CoV-mediated" exact="disease" post="(138). Mannose-binding lectin (MBL) is a pattern recognition molecule,"/>
  <result pre="microbial surface, thereby activating complement terminal pathways (139). MBL serum" exact="immunodeficiency" post="has been suggested to play a role, although controversial,"/>
  <result pre="been suggested to play a role, although controversial, in increased" exact="susceptibility to" post="a wide range of viral and bacterial infections, mainly"/>
  <result pre="although controversial, in increased susceptibility to a wide range of" exact="viral" post="and bacterial infections, mainly in children (140â€&quot;142). A single"/>
  <result pre="in increased susceptibility to a wide range of viral and" exact="bacterial infections," post="mainly in children (140â€&quot;142). A single study has identified"/>
  <result pre="immunity, the impact of PIDs associated with antibody deficiencies and" exact="combined immunodeficiencies" post="on SARS-CoV-2 outcomes are not fully clarified. However, some"/>
  <result pre="retrieved from a description of severe lung pathology and COVID-19" exact="disease" post="course in patients with common variable immunodeficiency (CVID) compared"/>
  <result pre="severe lung pathology and COVID-19 disease course in patients with" exact="common variable immunodeficiency" post="(CVID) compared to patients with pure agammaglobulinemia (144). Although"/>
  <result pre="pathology and COVID-19 disease course in patients with common variable" exact="immunodeficiency" post="(CVID) compared to patients with pure agammaglobulinemia (144). Although"/>
  <result pre="with common variable immunodeficiency (CVID) compared to patients with pure" exact="agammaglobulinemia" post="(144). Although the results were based on few patients,"/>
  <result pre="based on few patients, it was noted that patients with" exact="agammaglobulinemia" post="experienced relatively mild disease. However, patients with similarly low"/>
  <result pre="phenotype and potentially excessive IL-6 production in COVID-19 pathogenesis, although" exact="T cell deficiency" post="may also be involved (144). Collectively, results of studies"/>
  <result pre="potentially excessive IL-6 production in COVID-19 pathogenesis, although T cell" exact="deficiency" post="may also be involved (144). Collectively, results of studies"/>
  <result pre="also be involved (144). Collectively, results of studies into COVID-19" exact="disease" post="presentation and progression in patients with known PIDs are"/>
  <result pre="from severe COVID-19, it would be expected that T cell" exact="lymphopenia" post="from any source might represent an increased risk of"/>
  <result pre="from any source might represent an increased risk of severe" exact="viral infection." post="However, not much evidence suggests that patients with primary"/>
  <result pre="viral infection. However, not much evidence suggests that patients with" exact="primary" post="T cell defects nor HIV infection are at a"/>
  <result pre="evidence suggests that patients with primary T cell defects nor" exact="HIV infection" post="are at a significantly elevated risk. When large cohort"/>
  <result pre="suggests that patients with primary T cell defects nor HIV" exact="infection" post="are at a significantly elevated risk. When large cohort"/>
  <result pre="of SARS-infected and MERS-CoV-infected patients from previous epidemics were reviewed," exact="HIV infection" post="was not identified as an independent risk factor for"/>
  <result pre="SARS-infected and MERS-CoV-infected patients from previous epidemics were reviewed, HIV" exact="infection" post="was not identified as an independent risk factor for"/>
  <result pre="infection was not identified as an independent risk factor for" exact="infection" post="by these coronaviruses (145, 146). However, evidence for the"/>
  <result pre="endothelial cell biology and regulation may be anticipated to aggravate" exact="coagulopathy" post="and thrombotic events. Specific evidence on such associations remains"/>
  <result pre="histocompatibility complex antigen loci (HLA) are well-known to influence host" exact="susceptibility to" post="infectious disease (149). So far, only a limited number"/>
  <result pre="antigen loci (HLA) are well-known to influence host susceptibility to" exact="infectious disease" post="(149). So far, only a limited number of studies"/>
  <result pre="loci (HLA) are well-known to influence host susceptibility to infectious" exact="disease" post="(149). So far, only a limited number of studies"/>
  <result pre="host susceptibility to infectious disease (149). So far, only a" exact="limited" post="number of studies have looked for an association between"/>
  <result pre="HLA haplotypes may identify some of the unexplained differences in" exact="disease" post="severity and mortality observed across different countries and different"/>
  <result pre="patients in Taiwan identified an association between HLA-B*4601 and SARS-CoV" exact="infection" post="(155); however, this was not confirmed in a study"/>
  <result pre="specificities for SARS-CoV-2 peptides may confer a more severe COVID-19" exact="disease" post="course (158). Zhao et al. (159) investigated the relationship"/>
  <result pre="disease, whilst having blood group O was associated with a" exact="lower" post="infection risk. A similar risk pattern for ABO blood"/>
  <result pre="whilst having blood group O was associated with a lower" exact="infection" post="risk. A similar risk pattern for ABO blood groups"/>
  <result pre="polymorphisms in the IL28B gene which have been linked to" exact="hepatitis C" post="virus (HCV) clearance (161). The product of this gene"/>
  <result pre="virus (HCV) clearance (161). The product of this gene is" exact="type III" post="IFN (IFN-Î»). Given that genetic variants in IFN-Î» appear"/>
  <result pre="to play an important role in the natural course of" exact="disease" post="and severity during infection with HCV, it will be"/>
  <result pre="role in the natural course of disease and severity during" exact="infection" post="with HCV, it will be interesting to investigate if"/>
  <result pre="from over 2.7 million app users. Analysis of same sex" exact="adult" post="twins (n = 2,000+) showed that genetic factors accounted"/>
  <result pre="how genetic differences may explain the great variability in SARS-CoV-2" exact="infection" post="outcome. As we start to gain further insight into"/>
  <result pre="whether there might be an increased risk of developing severe" exact="disease" post="in certain individuals, and whether genes predisposing to those"/>
  <result pre="(163). Focus should also be on known genetic causes of" exact="hemophagocytic lymphohistiocytosis" post="(HLH), including defects in the genes PRF1, UNC13D, STX11,"/>
  <result pre="as SARS-CoV-2 (165). However, the precise pathogenesis of macrophage activation" exact="syndrome" post="and Kawasaki-like disease/PIMS in COVID-19 is not fully understood"/>
  <result pre="and/or immunopathology induced directly by the virus or as a" exact="secondary" post="result of crossreactivity. At the other end of the"/>
  <result pre="secondary result of crossreactivity. At the other end of the" exact="disease" post="spectrum, there is the possibility that some individuals may"/>
  <result pre="spectrum, there is the possibility that some individuals may avoid" exact="infection" post="due to protective tissue types or gene mutations. The"/>
  <result pre="cells restistant to SARS-CoV-2 infection, in analogy to protection from" exact="HIV infection" post="by Delta32 CCR5 homozygosity (166). Given the important role"/>
  <result pre="restistant to SARS-CoV-2 infection, in analogy to protection from HIV" exact="infection" post="by Delta32 CCR5 homozygosity (166). Given the important role"/>
  <result pre="ACE2, which are predicted to modify virus-host interaction and alter" exact="susceptibility to" post="SARS-CoV-2 (167). Another study has also reported rare, genetic"/>
  <result pre="has also reported rare, genetic variants in TMPRSS2 as possible" exact="disease" post="modulators of SARS-CoV-2 infection in Italy (168). Although these"/>
  <result pre="genetic variants in TMPRSS2 as possible disease modulators of SARS-CoV-2" exact="infection" post="in Italy (168). Although these findings necessitate functional validation,"/>
  <result pre="to the hypothesis that rare, genetic mutations may explain COVID-19" exact="disease" post="severity. Therapeutic Developments and Trials No therapeutics have yet"/>
  <result pre="remdesivir significantly shortened the time to recovery in patients with" exact="lower" post="airway involvement, and interestingly, another study found no difference"/>
  <result pre="responses may be major determinants at that stage, rather than" exact="viral" post="replication. Promising results in controlling SARS-CoV-2 in vitro have"/>
  <result pre="for chloroquine and hydroxychloroquine presently used in the treatment of" exact="malaria" post="and autoimmune diseases (175, 186, 187). However, a randomized"/>
  <result pre="and hydroxychloroquine presently used in the treatment of malaria and" exact="autoimmune diseases" post="(175, 186, 187). However, a randomized trial including 199"/>
  <result pre="model (199). Camostat mesylate is widely used in Japan for" exact="chronic" post="pancreatitis and postoperative reflux esophagitis (200, 201), and currently,"/>
  <result pre="(199). Camostat mesylate is widely used in Japan for chronic" exact="pancreatitis" post="and postoperative reflux esophagitis (200, 201), and currently, a"/>
  <result pre="is widely used in Japan for chronic pancreatitis and postoperative" exact="reflux" post="esophagitis (200, 201), and currently, a clinical trial in"/>
  <result pre="widely used in Japan for chronic pancreatitis and postoperative reflux" exact="esophagitis" post="(200, 201), and currently, a clinical trial in Denmark"/>
  <result pre="publications on potential COVID-19 therapeutics, thus far only a very" exact="limited" post="number of well-designed clinical trials are available. However, to"/>
  <result pre="role of human genetics in the face of a novel" exact="infectious disease." post="Sequencing children and young or middle-aged individuals with severe"/>
  <result pre="healthy, will identify rare, deleterious mutations that lead to SARS-CoV-2" exact="infection" post="and severe clinical outcome. This will offer unique insights"/>
  <result pre="severe clinical outcome. This will offer unique insights on the" exact="disease" post="pathogenesis in natura, which will undoubtedly offer new therapeutic"/>
  <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
  <result pre="References References 1.ZhuNZhangDWangWLiXYangBSongJet al.. A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019. N Engl J Med. (2020) 382:727â€&quot;33."/>
  <result pre="(2020) 382:727â€&quot;33. 10.1056/NEJMoa200101731978945 2.RothanHAByrareddySN. The epidemiology and pathogenesis of coronavirus" exact="disease" post="(COVID-19) outbreak. J Autoimmun. (2020) 109:102433. 10.1016/j.jaut.2020.10243332113704 3.ChannappanavarRPerlmanS. Pathogenic"/>
  <result pre="from basic biology to roles in infection, protective immunity, and" exact="primary" post="immunodeficiencies. Front Immunol. (2018) 9:3047. 10.3389/fimmu.2018.0304730671054 7.BousfihaAJeddaneLPicardCAilalFBobby GasparHAl-HerzWet al.."/>
  <result pre="10.3389/fimmu.2018.0304730671054 7.BousfihaAJeddaneLPicardCAilalFBobby GasparHAl-HerzWet al.. The 2017. IUIS phenotypic classification for" exact="primary" post="immunodeficiencies. J Clin Immunol. (2018) 38:129â€&quot;43. 10.1007/s10875-017-0465-829226301 8.CasanovaJLAbelL. Human"/>
  <result pre="J Clin Immunol. (2018) 38:129â€&quot;43. 10.1007/s10875-017-0465-829226301 8.CasanovaJLAbelL. Human genetics of" exact="infectious" post="diseases: unique insights into immunological redundancy. Semin Immunol. (2018)"/>
  <result pre="(2018) 36:1â€&quot;12. 10.1016/j.smim.2017.12.00829254755 9.JouanguyEBeziatVMogensenTHCasanovaJLTangyeSGZhangSY. Human inborn errors of immunity to" exact="herpes" post="viruses. Curr Opin Immunol. (2020) 62:106â€&quot;22. 10.1016/j.coi.2020.01.00432014647 10.CasanovaJLAbelL. The"/>
  <result pre="(2020) 62:106â€&quot;22. 10.1016/j.coi.2020.01.00432014647 10.CasanovaJLAbelL. The human genetic determinism of life-threatening" exact="infectious" post="diseases: genetic heterogeneity and physiological homogeneity?Hum Genet. (2020) 139:681â€&quot;94."/>
  <result pre="and physiological homogeneity?Hum Genet. (2020) 139:681â€&quot;94. 10.1007/s00439-020-02184-w32462426 11.ZhangSYJouanguyEUgoliniSSmahiAElainGRomeroPet al.. TLR3" exact="deficiency" post="in patients with herpes simplex encephalitis. Science. (2007) 317:1522â€&quot;7."/>
  <result pre="(2020) 139:681â€&quot;94. 10.1007/s00439-020-02184-w32462426 11.ZhangSYJouanguyEUgoliniSSmahiAElainGRomeroPet al.. TLR3 deficiency in patients with" exact="herpes" post="simplex encephalitis. Science. (2007) 317:1522â€&quot;7. 10.1126/science.113952217872438 12.ZhangSYClarkNEFreijeCAPauwelsETaggartAJOkadaSet al.. Inborn"/>
  <result pre="Inborn errors of RNA lariat metabolism in humans with brainstem" exact="viral infection." post="Cell. (2018) 172:952â€&quot;65.e18. 10.1016/j.cell.2018.02.01929474921 13.OgunjimiBZhangSYSorensenKBSkipperKACarter-TimofteMKernerGet al.. Inborn errors in"/>
  <result pre="al.. Inborn errors in RNA polymerase III underlie severe varicella" exact="zoster" post="virus infections. J Clin Invest. (2017) 127:3543â€&quot;56. 10.1172/JCI9228028783042 14.Carter-TimofteMEHansenAFChristiansenMPaludanSRMogensenTH."/>
  <result pre="Genes Immun. (2019) 20:214â€&quot;23. 10.1038/s41435-018-0027-y29728610 15.Carter-TimofteMEHansenAFMardahlMFribourgSRapaportFZhangS-Yet al.. Varicella-zoster virus CNS" exact="vasculitis" post="and RNA polymerase III gene mutation in identical twins."/>
  <result pre="identical twins. Neurol. Neuroimmunol. Neuroinflamm. (2018) 5:e500. 10.1212/NXI.000000000000050030211253 16.CiancanelliMJHuangSXLuthraPGarnerHItanYVolpiSet al.." exact="Infectious" post="disease. Life-threatening influenza and impaired interferon amplification in human"/>
  <result pre="IRF9 deficiency. J Exp Med. (2018) 215:2567â€&quot;85. 10.1084/jem.2018062830143481 18.LimHKHuangSXLChenJKernerGGilliauxOBastardPet al.." exact="Severe" post="influenza pneumonitis in children with inherited TLR3 deficiency. J"/>
  <result pre="Exp Med. (2019) 216:2038â€&quot;56. 10.1084/jem.2018162131217193 19.SologurenIMartinez-SaavedraMTSole-ViolanJde Borges de OliveiraEJrBetancorECasasIet al.." exact="Lethal" post="influenza in two related adults with inherited GATA2 deficiency."/>
  <result pre="20.JorgensenSEChristiansenMRyoLBGadHHGjedstedJStaeheliPet al.. Defective RNA sensing by RIG-I in severe influenza" exact="virus infection." post="Clin Exp Immunol. (2018) 192:366â€&quot;76. 10.1111/cei.1312029453856 21.LambornITJingHZhangYDrutmanSBAbbottJKMunirSet al.. Recurrent"/>
  <result pre="virus infection. Clin Exp Immunol. (2018) 192:366â€&quot;76. 10.1111/cei.1312029453856 21.LambornITJingHZhangYDrutmanSBAbbottJKMunirSet al.." exact="Recurrent" post="rhinovirus infections in a child with inherited MDA5 deficiency."/>
  <result pre="Clin Exp Immunol. (2018) 192:366â€&quot;76. 10.1111/cei.1312029453856 21.LambornITJingHZhangYDrutmanSBAbbottJKMunirSet al.. Recurrent rhinovirus" exact="infections" post="in a child with inherited MDA5 deficiency. J Exp"/>
  <result pre="natural killer cells to kill Epstein-Barr virus-infected B cells in" exact="X-linked" post="lymphoproliferative disease. J Exp Med. (2001) 194:235â€&quot;46. 10.1084/jem.194.3.23511489943 24.SalzerEDaschkeySChooSGombertMSantos-ValenteEGinzelSet"/>
  <result pre="killer cells to kill Epstein-Barr virus-infected B cells in X-linked" exact="lymphoproliferative disease." post="J Exp Med. (2001) 194:235â€&quot;46. 10.1084/jem.194.3.23511489943 24.SalzerEDaschkeySChooSGombertMSantos-ValenteEGinzelSet al.. Combined"/>
  <result pre="lymphoproliferative disease. J Exp Med. (2001) 194:235â€&quot;46. 10.1084/jem.194.3.23511489943 24.SalzerEDaschkeySChooSGombertMSantos-ValenteEGinzelSet al.." exact="Combined" post="immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking"/>
  <result pre="disease. J Exp Med. (2001) 194:235â€&quot;46. 10.1084/jem.194.3.23511489943 24.SalzerEDaschkeySChooSGombertMSantos-ValenteEGinzelSet al.. Combined" exact="immunodeficiency" post="with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional"/>
  <result pre="CD27. Haematologica. (2013) 98:473â€&quot;8. 10.3324/haematol.2012.06879122801960 25.MarshRAMaddenLKitchenBJModyRMcClimonBJordanMBet al.XIAP deficiency: a unique" exact="primary" post="immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and"/>
  <result pre="Haematologica. (2013) 98:473â€&quot;8. 10.3324/haematol.2012.06879122801960 25.MarshRAMaddenLKitchenBJModyRMcClimonBJordanMBet al.XIAP deficiency: a unique primary" exact="immunodeficiency" post="best classified as X-linked familial hemophagocytic lymphohistiocytosis and not"/>
  <result pre="25.MarshRAMaddenLKitchenBJModyRMcClimonBJordanMBet al.XIAP deficiency: a unique primary immunodeficiency best classified as" exact="X-linked" post="familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease."/>
  <result pre="al.XIAP deficiency: a unique primary immunodeficiency best classified as X-linked" exact="familial" post="hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood."/>
  <result pre="deficiency: a unique primary immunodeficiency best classified as X-linked familial" exact="hemophagocytic lymphohistiocytosis" post="and not as X-linked lymphoproliferative disease. Blood. (2010) 116:1079â€&quot;82."/>
  <result pre="best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as" exact="X-linked" post="lymphoproliferative disease. Blood. (2010) 116:1079â€&quot;82. 10.1182/blood-2010-01-25609920489057 26.LinkaRMRisseSLBienemannKWernerMLinkaYKruxFet al.. Loss-of-function"/>
  <result pre="classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked" exact="lymphoproliferative disease." post="Blood. (2010) 116:1079â€&quot;82. 10.1182/blood-2010-01-25609920489057 26.LinkaRMRisseSLBienemannKWernerMLinkaYKruxFet al.. Loss-of-function mutations within"/>
  <result pre="diseases. Leukemia. (2012) 26:963â€&quot;71. 10.1038/leu.2011.37122289921 27.LiFYChaigne-DelalandeBSuHUzelGMatthewsHLenardoMJ. XMEN disease: a new" exact="primary" post="immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus."/>
  <result pre="Leukemia. (2012) 26:963â€&quot;71. 10.1038/leu.2011.37122289921 27.LiFYChaigne-DelalandeBSuHUzelGMatthewsHLenardoMJ. XMEN disease: a new primary" exact="immunodeficiency" post="affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood."/>
  <result pre="against Epstein-Barr virus. Blood. (2014) 123:2148â€&quot;52. 10.1182/blood-2013-11-53868624550228 28.DrutmanSBMansouriDMahdavianiSANeehusALHumDBrykRet al.. Fatal" exact="cytomegalovirus infection" post="in an adult with inherited NOS2 deficiency. N Engl"/>
  <result pre="Epstein-Barr virus. Blood. (2014) 123:2148â€&quot;52. 10.1182/blood-2013-11-53868624550228 28.DrutmanSBMansouriDMahdavianiSANeehusALHumDBrykRet al.. Fatal cytomegalovirus" exact="infection" post="in an adult with inherited NOS2 deficiency. N Engl"/>
  <result pre="(2014) 123:2148â€&quot;52. 10.1182/blood-2013-11-53868624550228 28.DrutmanSBMansouriDMahdavianiSANeehusALHumDBrykRet al.. Fatal cytomegalovirus infection in an" exact="adult" post="with inherited NOS2 deficiency. N Engl J Med. (2020)"/>
  <result pre="N Engl J Med. (2020) 382:437â€&quot;45. 10.1056/NEJMoa191064031995689 29.HambletonSGoodbournSYoungDFDickinsonPMohamadSMValappilMet al.. STAT2" exact="deficiency" post="and susceptibility to viral illness in humans. Proc Natl"/>
  <result pre="J Med. (2020) 382:437â€&quot;45. 10.1056/NEJMoa191064031995689 29.HambletonSGoodbournSYoungDFDickinsonPMohamadSMValappilMet al.. STAT2 deficiency and" exact="susceptibility to" post="viral illness in humans. Proc Natl Acad Sci USA."/>
  <result pre="(2020) 382:437â€&quot;45. 10.1056/NEJMoa191064031995689 29.HambletonSGoodbournSYoungDFDickinsonPMohamadSMValappilMet al.. STAT2 deficiency and susceptibility to" exact="viral" post="illness in humans. Proc Natl Acad Sci USA. (2013)"/>
  <result pre="Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
  <result pre="10.1016/j.jinf.2020.03.006 36.WuZMcGooganJM. Characteristics of and important lessons from the coronavirus" exact="disease" post="2019. (COVID-19) outbreak in China: summary of a report"/>
  <result pre="a report of 72314 cases from the chinese center for" exact="disease" post="control and prevention. JAMA. (2020). [Epub ahead of print]."/>
  <result pre="Clinical characteristics of 138 hospitalized patients with 2019. novel coronavirus-infected" exact="pneumonia" post="in Wuhan, China. JAMA. (2020) 323:1061â€&quot;9. 10.1001/jama.2020.158532031570 38.GuanWJNiZYHuYLiangWHOuCQHeJXet al.Clinical"/>
  <result pre="China. JAMA. (2020) 323:1061â€&quot;9. 10.1001/jama.2020.158532031570 38.GuanWJNiZYHuYLiangWHOuCQHeJXet al.Clinical characteristics of coronavirus" exact="disease" post="2019 in China. N Engl J Med. (2020) 382:1708â€&quot;20."/>
  <result pre="as a clinical presentation of mild-to-moderate forms of the coronavirus" exact="disease" post="(COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol. (2020)"/>
  <result pre="Sci. (2020) 414:116884. 10.1016/j.jns.2020.11688432464367 42.CheungKSHungIFChanPPLungKCTsoELiuRet al.. Gastrointestinal manifestations of SARS-CoV-2" exact="infection" post="and virus load in fecal samples from the hong"/>
  <result pre="Med. (2020) 8:e24. 10.1016/S2213-2600(20)30119-332178774 44.ConnorsJMLevyJH. COVID-19 and its implications for" exact="thrombosis" post="and anticoagulation. Blood. (2020) 135:2033â€&quot;40. 10.1182/blood.202000600032339221 45.DolhnikoffMDuarte-NetoANde Almeida MonteiroRAda"/>
  <result pre="10.1182/blood.202000600032339221 45.DolhnikoffMDuarte-NetoANde Almeida MonteiroRAda SilvaLFFde OliveiraEPSaldivaPHNet al.. Pathological evidence of" exact="pulmonary" post="thrombotic phenomena in severe COVID-19. J Thromb Haemost. (2020)"/>
  <result pre="Haemost. (2020) 18:1517â€&quot;9. 10.1111/jth.1484432294295 46.Al-SamkariHKarp LeafRSDzikWHCarlsonJCFogertyAEWaheedAet al.. COVID and coagulation:" exact="bleeding" post="and thrombotic manifestations of SARS-CoV2 Infection. Blood. (2020). [Epub"/>
  <result pre="10.1007/s00414-020-02317-w32500199 48.Lagunas-RangelFAChavez-ValenciaV. High IL-6/IFN-gamma ratio could be associated with severe" exact="disease" post="in COVID-19 patients. J Med Virol. (2020). [Epub ahead"/>
  <result pre="al.. On the alert for cytokine storm: immunopathology in COVID-19." exact="Arthritis" post="Rheumatol. (2020). [Epub ahead of print]. 10.1002/art.41285.32293098 50.CaoX. COVID-19:"/>
  <result pre="and receptor binding. Lancet. (2020) 395:565â€&quot;74. 10.1016/S0140-6736(20)30251-832007145 58.ZhouPYangXLWangXGHuBZhangLZhangWet al.. A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="origin. Nature. (2020) 579:270â€&quot;3. 10.1038/s41586-020-2012-732015507 59.LiXZaiJZhaoQNieQLiYFoleyBTet al.. Evolutionary history, potential" exact="intermediate" post="animal host, and cross-species analyses of SARS-CoV-2. J Med"/>
  <result pre="Nature. (2003) 426:450â€&quot;4. 10.1038/nature0214514647384 63.MatsuyamaSNagataNShiratoKKawaseMTakedaMTaguchiF. Efficient activation of the severe" exact="acute" post="respiratory syndrome coronavirus spike protein by the transmembrane protease"/>
  <result pre="(2003) 426:450â€&quot;4. 10.1038/nature0214514647384 63.MatsuyamaSNagataNShiratoKKawaseMTakedaMTaguchiF. Efficient activation of the severe acute" exact="respiratory" post="syndrome coronavirus spike protein by the transmembrane protease TMPRSS2."/>
  <result pre="426:450â€&quot;4. 10.1038/nature0214514647384 63.MatsuyamaSNagataNShiratoKKawaseMTakedaMTaguchiF. Efficient activation of the severe acute respiratory" exact="syndrome" post="coronavirus spike protein by the transmembrane protease TMPRSS2. J"/>
  <result pre="64.ShullaAHeald-SargentTSubramanyaGZhaoJPerlmanSGallagherT. A transmembrane serine protease is linked to the severe" exact="acute" post="respiratory syndrome coronavirus receptor and activates virus entry. J"/>
  <result pre="A transmembrane serine protease is linked to the severe acute" exact="respiratory" post="syndrome coronavirus receptor and activates virus entry. J Virol."/>
  <result pre="transmembrane serine protease is linked to the severe acute respiratory" exact="syndrome" post="coronavirus receptor and activates virus entry. J Virol. (2011)"/>
  <result pre="al.. Clinical and immunologic features in severe and moderate Coronavirus" exact="Disease" post="2019. J Clin Invest. (2020) 130:2620â€&quot;9. 10.1101/2020.02.16.2002390332217835 74.PrompetcharaEKetloyCPalagaT. Immune"/>
  <result pre="TRIF contributes to a protective innate immune response to severe" exact="acute" post="respiratory syndrome coronavirus infection. mBio. (2015) 6:e00638â€&quot;15. 10.1128/mBio.00638-1526015500 78.SheahanTMorrisonTEFunkhouserWUematsuSAkiraSBaricRSet"/>
  <result pre="contributes to a protective innate immune response to severe acute" exact="respiratory" post="syndrome coronavirus infection. mBio. (2015) 6:e00638â€&quot;15. 10.1128/mBio.00638-1526015500 78.SheahanTMorrisonTEFunkhouserWUematsuSAkiraSBaricRSet al.."/>
  <result pre="to a protective innate immune response to severe acute respiratory" exact="syndrome" post="coronavirus infection. mBio. (2015) 6:e00638â€&quot;15. 10.1128/mBio.00638-1526015500 78.SheahanTMorrisonTEFunkhouserWUematsuSAkiraSBaricRSet al.. MyD88"/>
  <result pre="10.1128/mBio.00638-1526015500 78.SheahanTMorrisonTEFunkhouserWUematsuSAkiraSBaricRSet al.. MyD88 is required for protection from lethal" exact="infection" post="with a mouse-adapted SARS-CoV. PLoS Pathog. (2008) 4:e1000240. 10.1371/journal.ppat.100024019079579"/>
  <result pre="7:1653â€&quot;63. 10.1534/g3.117.04143428592648 80.CameronMJRanLXuLDaneshABermejo-MartinJFCameronCMet al.. Interferon-mediated immunopathological events are associated with" exact="atypical" post="innate and adaptive immune responses in patients with severe"/>
  <result pre="atypical innate and adaptive immune responses in patients with severe" exact="acute" post="respiratory syndrome. J Virol. (2007) 81:8692â€&quot;706. 10.1128/JVI.00527-0717537853 81.FaureEPoissyJGoffardAFournierCKipnisETitecatMet al.."/>
  <result pre="innate and adaptive immune responses in patients with severe acute" exact="respiratory" post="syndrome. J Virol. (2007) 81:8692â€&quot;706. 10.1128/JVI.00527-0717537853 81.FaureEPoissyJGoffardAFournierCKipnisETitecatMet al.. Distinct"/>
  <result pre="bench to bedside?PLoS One. (2014) 9:e88716. 10.1371/journal.pone.008871624551142 82.KuCLvon BernuthHPicardCZhangSYChangHHYangKet al.." exact="Selective" post="predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs"/>
  <result pre="One. (2014) 9:e88716. 10.1371/journal.pone.008871624551142 82.KuCLvon BernuthHPicardCZhangSYChangHHYangKet al.. Selective predisposition to" exact="bacterial infections" post="in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in"/>
  <result pre="(2014) 9:e88716. 10.1371/journal.pone.008871624551142 82.KuCLvon BernuthHPicardCZhangSYChangHHYangKet al.. Selective predisposition to bacterial" exact="infections" post="in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in"/>
  <result pre="in protective immunity. J Exp Med. (2007) 204:2407â€&quot;22. 10.1084/jem.2007062817893200 83.CasanovaJLAbelL." exact="Lethal" post="infectious diseases as inborn errors of immunity: toward a"/>
  <result pre="protective immunity. J Exp Med. (2007) 204:2407â€&quot;22. 10.1084/jem.2007062817893200 83.CasanovaJLAbelL. Lethal" exact="infectious diseases" post="as inborn errors of immunity: toward a synthesis of"/>
  <result pre="print]. 10.1146/annurev-pathol-031920-101429.32289233 84.ZalingerZBElliottRRoseKMWeissSR. MDA5 Is Critical to Host Defense during" exact="Infection" post="with Murine Coronavirus. J Virol. (2015) 89:12330â€&quot;40. 10.1128/JVI.01470-1526423942 85.MenacheryVDDebbinkKBaricRS."/>
  <result pre="(2014) 194:191â€&quot;9. 10.1016/j.virusres.2014.09.00925278144 86.MenacheryVDYountBLJr.JossetLGralinskiLEScobeyTet al.. Attenuation and restoration of severe" exact="acute" post="respiratory syndrome coronavirus mutant lacking 2'-o-methyltransferase activity. J Virol."/>
  <result pre="194:191â€&quot;9. 10.1016/j.virusres.2014.09.00925278144 86.MenacheryVDYountBLJr.JossetLGralinskiLEScobeyTet al.. Attenuation and restoration of severe acute" exact="respiratory" post="syndrome coronavirus mutant lacking 2'-o-methyltransferase activity. J Virol. (2014)"/>
  <result pre="10.1016/j.virusres.2014.09.00925278144 86.MenacheryVDYountBLJr.JossetLGralinskiLEScobeyTet al.. Attenuation and restoration of severe acute respiratory" exact="syndrome" post="coronavirus mutant lacking 2'-o-methyltransferase activity. J Virol. (2014) 88:4251â€&quot;64."/>
  <result pre="and lethal influenza disease. Science. (2016) 352:463â€&quot;6. 10.1126/science.aaf392627102485 89.Nieto-TorresJLVerdia-BaguenaCJimenez-GuardenoJMRegla-NavaJACastano-RodriguezCFernandez-DelgadoRet al.." exact="Severe" post="acute respiratory syndrome coronavirus E protein transports calcium ions"/>
  <result pre="lethal influenza disease. Science. (2016) 352:463â€&quot;6. 10.1126/science.aaf392627102485 89.Nieto-TorresJLVerdia-BaguenaCJimenez-GuardenoJMRegla-NavaJACastano-RodriguezCFernandez-DelgadoRet al.. Severe" exact="acute" post="respiratory syndrome coronavirus E protein transports calcium ions and"/>
  <result pre="influenza disease. Science. (2016) 352:463â€&quot;6. 10.1126/science.aaf392627102485 89.Nieto-TorresJLVerdia-BaguenaCJimenez-GuardenoJMRegla-NavaJACastano-RodriguezCFernandez-DelgadoRet al.. Severe acute" exact="respiratory" post="syndrome coronavirus E protein transports calcium ions and activates"/>
  <result pre="disease. Science. (2016) 352:463â€&quot;6. 10.1126/science.aaf392627102485 89.Nieto-TorresJLVerdia-BaguenaCJimenez-GuardenoJMRegla-NavaJACastano-RodriguezCFernandez-DelgadoRet al.. Severe acute respiratory" exact="syndrome" post="coronavirus E protein transports calcium ions and activates the"/>
  <result pre="activates NLRP3 inflammasomes. Cell Death Discov. (2019) 5:101. 10.1038/s41420-019-0181-731231549 91.ChenIYMoriyamaMChangMFIchinoheT." exact="Severe" post="acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3"/>
  <result pre="NLRP3 inflammasomes. Cell Death Discov. (2019) 5:101. 10.1038/s41420-019-0181-731231549 91.ChenIYMoriyamaMChangMFIchinoheT. Severe" exact="acute" post="respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome."/>
  <result pre="inflammasomes. Cell Death Discov. (2019) 5:101. 10.1038/s41420-019-0181-731231549 91.ChenIYMoriyamaMChangMFIchinoheT. Severe acute" exact="respiratory" post="syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front"/>
  <result pre="Cell Death Discov. (2019) 5:101. 10.1038/s41420-019-0181-731231549 91.ChenIYMoriyamaMChangMFIchinoheT. Severe acute respiratory" exact="syndrome" post="coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol."/>
  <result pre="Dis. (2004) 36:829â€&quot;31. 10.1080/0036554041002114415764169 96.HaagmansBLKuikenTMartinaBEFouchierRARimmelzwaanGFvan AmerongenGet al.. Pegylated interferon-alpha protects" exact="type 1" post="pneumocytes against SARS coronavirus infection in macaques. Nat Med."/>
  <result pre="al.. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaques. Nat Med. (2004) 10:290â€&quot;3. 10.1038/nm100114981511 97.SainzBJr.MosselECPetersCJGarryRF. Interferon-beta"/>
  <result pre="97.SainzBJr.MosselECPetersCJGarryRF. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe" exact="acute" post="respiratory syndrome-associated coronavirus (SARS-CoV). Virology. (2004) 329:11â€&quot;7. 10.1016/j.virol.2004.08.01115476870 98.StroherUDiCaroALiYStrongJEAokiFPlummerFet"/>
  <result pre="Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute" exact="respiratory" post="syndrome-associated coronavirus (SARS-CoV). Virology. (2004) 329:11â€&quot;7. 10.1016/j.virol.2004.08.01115476870 98.StroherUDiCaroALiYStrongJEAokiFPlummerFet al.."/>
  <result pre="respiratory syndrome-associated coronavirus (SARS-CoV). Virology. (2004) 329:11â€&quot;7. 10.1016/j.virol.2004.08.01115476870 98.StroherUDiCaroALiYStrongJEAokiFPlummerFet al.." exact="Severe" post="acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha."/>
  <result pre="syndrome-associated coronavirus (SARS-CoV). Virology. (2004) 329:11â€&quot;7. 10.1016/j.virol.2004.08.01115476870 98.StroherUDiCaroALiYStrongJEAokiFPlummerFet al.. Severe" exact="acute" post="respiratory syndrome-related coronavirus is inhibited by interferon- alpha. J"/>
  <result pre="coronavirus (SARS-CoV). Virology. (2004) 329:11â€&quot;7. 10.1016/j.virol.2004.08.01115476870 98.StroherUDiCaroALiYStrongJEAokiFPlummerFet al.. Severe acute" exact="respiratory" post="syndrome-related coronavirus is inhibited by interferon- alpha. J Infect"/>
  <result pre="10.1016/S0140-6736(03)13973-612892961 101.ToturaALBaricRS. SARS coronavirus pathogenesis: host innate immune responses and" exact="viral" post="antagonism of interferon. Curr Opin Virol. (2012) 2:264â€&quot;75. 10.1016/j.coviro.2012.04.00422572391"/>
  <result pre="10.1016/j.coviro.2012.04.00422572391 102.YoshikawaTHillTEYoshikawaNPopovVLGalindoCLGarnerHRet al.. Dynamic innate immune responses of human bronchial" exact="epithelial" post="cells to severe acute respiratory syndrome-associated coronavirus infection. PLoS"/>
  <result pre="innate immune responses of human bronchial epithelial cells to severe" exact="acute" post="respiratory syndrome-associated coronavirus infection. PLoS One. (2010) 5:e8729. 10.1371/journal.pone.000872920090954"/>
  <result pre="immune responses of human bronchial epithelial cells to severe acute" exact="respiratory" post="syndrome-associated coronavirus infection. PLoS One. (2010) 5:e8729. 10.1371/journal.pone.000872920090954 103.Blanco-MeloDNilsson-PayantBELiuWCUhlSHoaglandDMollerRet"/>
  <result pre="of print]. 10.1093/cid/ciaa410.32270184 105.KindlerEThielV. To sense or not to sense" exact="viral" post="RNAâ€&quot;essentials of coronavirus innate immune evasion. Curr Opin Microbiol."/>
  <result pre="Res. (2016) 96:219â€&quot;43. 10.1016/bs.aivir.2016.08.00627712625 108.ChannappanavarRZhaoJPerlmanS. T cell-mediated immune response to" exact="respiratory" post="coronaviruses. Immunol Res. (2014) 59:118â€&quot;28. 10.1007/s12026-014-8534-z24845462 109.LiCKWuHYanHMaSWangLZhangMet al.. T"/>
  <result pre="and functional exhaustion of t cells in patients with coronavirus" exact="disease" post="2019. (COVID-19). Front Immunol. (2020) 11:827. 10.3389/fimmu.2020.0082732425950 113.ZhengHYZhangMYangCXZhangNWangXCYangXPet al.."/>
  <result pre="disease 2019. (COVID-19). Front Immunol. (2020) 11:827. 10.3389/fimmu.2020.0082732425950 113.ZhengHYZhangMYangCXZhangNWangXCYangXPet al.." exact="Elevated" post="exhaustion levels and reduced functional diversity of T cells"/>
  <result pre="exhaustion levels and reduced functional diversity of T cells in" exact="peripheral" post="blood may predict severe progression in COVID-19 patients. Cell"/>
  <result pre="T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19" exact="disease" post="and unexposed individuals. Cell. (2020). [Epub ahead of print]."/>
  <result pre="memory CD8 T cells provide substantial protection from lethal severe" exact="acute" post="respiratory syndrome coronavirus infection. J Virol. (2014) 88:11034â€&quot;44. 10.1128/JVI.01505-1425056892"/>
  <result pre="CD8 T cells provide substantial protection from lethal severe acute" exact="respiratory" post="syndrome coronavirus infection. J Virol. (2014) 88:11034â€&quot;44. 10.1128/JVI.01505-1425056892 116.XuZShiLWangYZhangJHuangLZhangCet"/>
  <result pre="T cells provide substantial protection from lethal severe acute respiratory" exact="syndrome" post="coronavirus infection. J Virol. (2014) 88:11034â€&quot;44. 10.1128/JVI.01505-1425056892 116.XuZShiLWangYZhangJHuangLZhangCet al.."/>
  <result pre="88:11034â€&quot;44. 10.1128/JVI.01505-1425056892 116.XuZShiLWangYZhangJHuangLZhangCet al.. Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndrome. Lancet Respir Med. (2020) 8:420â€&quot;2. 10.1016/S2213-2600(20)30076-X32085846"/>
  <result pre="10.1128/JVI.01505-1425056892 116.XuZShiLWangYZhangJHuangLZhangCet al.. Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndrome. Lancet Respir Med. (2020) 8:420â€&quot;2. 10.1016/S2213-2600(20)30076-X32085846 117.LiaoMLiuYYuanJWenYXuGZhaoJet"/>
  <result pre="Dysregulated type i interferon and inflammatory monocyte-macrophage responses cause lethal" exact="pneumonia" post="in SARS-CoV-infected Mice. Cell Host Microbe. (2016) 19:181â€&quot;93. 10.1016/j.chom.2016.01.00726867177"/>
  <result pre="Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after" exact="infection" post="with SARS-associated coronavirus. Clin Microbiol Infect. (2004) 10:1062â€&quot;6. 10.1111/j.1469-0691.2004.01009.x15606632"/>
  <result pre="10.1056/NEJM20030731349052012890855 123.KellamPBarclayW. The dynamics of humoral immune responses following SARS-CoV-2" exact="infection" post="and the potential for reinfection. J Gen Virol. (2020)."/>
  <result pre="Gen Virol. (2020). [Epub ahead of print]. 10.1099/jgv.0.001439.32430094 124.LongQXLiuBZDengHJWuGCDengKChenYKet al.." exact="Antibody" post="responses to SARS-CoV-2 in patients with COVID-19. Nat Med."/>
  <result pre="125.ZhaoJYuanQWangHLiuWLiaoXSuYet al.Antibody responses to SARS-CoV-2 in patients of novel coronavirus" exact="disease" post="2019. Clin Infect Dis. (2020). [Epub ahead of print]."/>
  <result pre="[Epub ahead of print]. 10.1093/cid/ciaa344. 126.ToKKTsangOTLeungWSTamARWuTCLungDCet al.. Temporal profiles of" exact="viral" post="load in posterior oropharyngeal saliva samples and serum antibody"/>
  <result pre="print]. 10.1093/cid/ciaa344. 126.ToKKTsangOTLeungWSTamARWuTCLungDCet al.. Temporal profiles of viral load in" exact="posterior" post="oropharyngeal saliva samples and serum antibody responses during infection"/>
  <result pre="in posterior oropharyngeal saliva samples and serum antibody responses during" exact="infection" post="by SARS-CoV-2: an observational cohort study. Lancet Infect Dis."/>
  <result pre="study of the humoral immune response of patients with severe" exact="acute" post="respiratory syndrome. J Infect Dis. (2006) 193:792â€&quot;5. 10.1086/50046916479513 128.WuLPWangNCChangYHTianXYNaDYZhangLYet"/>
  <result pre="of the humoral immune response of patients with severe acute" exact="respiratory" post="syndrome. J Infect Dis. (2006) 193:792â€&quot;5. 10.1086/50046916479513 128.WuLPWangNCChangYHTianXYNaDYZhangLYet al.."/>
  <result pre="193:792â€&quot;5. 10.1086/50046916479513 128.WuLPWangNCChangYHTianXYNaDYZhangLYet al.. Duration of antibody responses after severe" exact="acute" post="respiratory syndrome. Emerg Infect Dis. (2007) 13:1562â€&quot;4. 10.3201/eid1310.07057618258008 129.NgOWChiaATanATJadiRSLeongHNBertolettiAet"/>
  <result pre="10.1086/50046916479513 128.WuLPWangNCChangYHTianXYNaDYZhangLYet al.. Duration of antibody responses after severe acute" exact="respiratory" post="syndrome. Emerg Infect Dis. (2007) 13:1562â€&quot;4. 10.3201/eid1310.07057618258008 129.NgOWChiaATanATJadiRSLeongHNBertolettiAet al.."/>
  <result pre="immunity. J Allergy Clin Immunol. (2019) 143:507â€&quot;27. 10.1016/j.jaci.2018.07.01330075154 132.ZieglerTMatikainenSRonkkoEOsterlundPSillanpaaMSirenJet al.." exact="Severe" post="acute respiratory syndrome coronavirus fails to activate cytokine-mediated innate"/>
  <result pre="J Allergy Clin Immunol. (2019) 143:507â€&quot;27. 10.1016/j.jaci.2018.07.01330075154 132.ZieglerTMatikainenSRonkkoEOsterlundPSillanpaaMSirenJet al.. Severe" exact="acute" post="respiratory syndrome coronavirus fails to activate cytokine-mediated innate immune"/>
  <result pre="Allergy Clin Immunol. (2019) 143:507â€&quot;27. 10.1016/j.jaci.2018.07.01330075154 132.ZieglerTMatikainenSRonkkoEOsterlundPSillanpaaMSirenJet al.. Severe acute" exact="respiratory" post="syndrome coronavirus fails to activate cytokine-mediated innate immune responses"/>
  <result pre="Clin Immunol. (2019) 143:507â€&quot;27. 10.1016/j.jaci.2018.07.01330075154 132.ZieglerTMatikainenSRonkkoEOsterlundPSillanpaaMSirenJet al.. Severe acute respiratory" exact="syndrome" post="coronavirus fails to activate cytokine-mediated innate immune responses in"/>
  <result pre="immunity. J Infect Dis. (2003) 187(Suppl. 2):S335â€&quot;9. 10.1086/37474612792848 140.KochAMelbyeMSorensenPHomoePMadsenHOMolbakKet al.." exact="Acute" post="respiratory tract infections and mannose-binding lectin insufficiency during early"/>
  <result pre="J Infect Dis. (2003) 187(Suppl. 2):S335â€&quot;9. 10.1086/37474612792848 140.KochAMelbyeMSorensenPHomoePMadsenHOMolbakKet al.. Acute" exact="respiratory" post="tract infections and mannose-binding lectin insufficiency during early childhood."/>
  <result pre="Dis. (2003) 187(Suppl. 2):S335â€&quot;9. 10.1086/37474612792848 140.KochAMelbyeMSorensenPHomoePMadsenHOMolbakKet al.. Acute respiratory tract" exact="infections" post="and mannose-binding lectin insufficiency during early childhood. JAMA. (2001)"/>
  <result pre="Association of variants of the gene for mannose-binding lectin with" exact="susceptibility to" post="meningococcal disease. Meningococcal Research Group. Lancet. (1999) 353:1049â€&quot;53. 10.1016/S0140-6736(98)08350-010199352"/>
  <result pre="disease. Meningococcal Research Group. Lancet. (1999) 353:1049â€&quot;53. 10.1016/S0140-6736(98)08350-010199352 142.GarredPMadsenHOBalslevUHofmannBPedersenCGerstoftJet al.." exact="Susceptibility to" post="HIV infection and progression of AIDS in relation to"/>
  <result pre="Research Group. Lancet. (1999) 353:1049â€&quot;53. 10.1016/S0140-6736(98)08350-010199352 142.GarredPMadsenHOBalslevUHofmannBPedersenCGerstoftJet al.. Susceptibility to" exact="HIV infection" post="and progression of AIDS in relation to variant alleles"/>
  <result pre="Group. Lancet. (1999) 353:1049â€&quot;53. 10.1016/S0140-6736(98)08350-010199352 142.GarredPMadsenHOBalslevUHofmannBPedersenCGerstoftJet al.. Susceptibility to HIV" exact="infection" post="and progression of AIDS in relation to variant alleles"/>
  <result pre="Lancet. (1997) 349:236â€&quot;40. 10.1016/S0140-6736(96)08440-19014910 143.IpWKChanKHLawHKTsoGHKongEKWongWHet al.. Mannose-binding lectin in severe" exact="acute" post="respiratory syndrome coronavirus infection. J Infect Dis. (2005) 191:1697â€&quot;704."/>
  <result pre="(1997) 349:236â€&quot;40. 10.1016/S0140-6736(96)08440-19014910 143.IpWKChanKHLawHKTsoGHKongEKWongWHet al.. Mannose-binding lectin in severe acute" exact="respiratory" post="syndrome coronavirus infection. J Infect Dis. (2005) 191:1697â€&quot;704. 10.1086/42963115838797"/>
  <result pre="349:236â€&quot;40. 10.1016/S0140-6736(96)08440-19014910 143.IpWKChanKHLawHKTsoGHKongEKWongWHet al.. Mannose-binding lectin in severe acute respiratory" exact="syndrome" post="coronavirus infection. J Infect Dis. (2005) 191:1697â€&quot;704. 10.1086/42963115838797 144.QuintiILougarisVMilitoCCinettoFPecoraroAMezzaromaIet"/>
  <result pre="[Epub ahead of print]. 10.1016/j.jaci.2020.04.013.32333914 145.PeirisJSChuCMChengVCChanKSHungIFPoonLLet al.. Clinical progression and" exact="viral" post="load in a community outbreak of coronavirus-associated SARS pneumonia:"/>
  <result pre="course and outcomes of critically ill patients with Middle East" exact="respiratory" post="syndrome coronavirus infection. Ann Intern Med. (2014) 160:389â€&quot;97. 10.7326/M13-248624474051"/>
  <result pre="and outcomes of critically ill patients with Middle East respiratory" exact="syndrome" post="coronavirus infection. Ann Intern Med. (2014) 160:389â€&quot;97. 10.7326/M13-248624474051 147.DaubyN."/>
  <result pre="Cell. (2020) 181:1194â€&quot;9. 10.1016/j.cell.2020.05.01632405102 149.MatzarakiVKumarVWijmengaCZhernakovaA. The MHC locus and genetic" exact="susceptibility to" post="autoimmune and infectious diseases. Genome Biol. (2017) 18:76. 10.1186/s13059-017-1207-128449694"/>
  <result pre="181:1194â€&quot;9. 10.1016/j.cell.2020.05.01632405102 149.MatzarakiVKumarVWijmengaCZhernakovaA. The MHC locus and genetic susceptibility to" exact="autoimmune" post="and infectious diseases. Genome Biol. (2017) 18:76. 10.1186/s13059-017-1207-128449694 150.DimarcoAD."/>
  <result pre="149.MatzarakiVKumarVWijmengaCZhernakovaA. The MHC locus and genetic susceptibility to autoimmune and" exact="infectious diseases." post="Genome Biol. (2017) 18:76. 10.1186/s13059-017-1207-128449694 150.DimarcoAD. Covid-19 and ethnicity:"/>
  <result pre="and inflammatory and pro-inflammatory factors in a community-based cohort study." exact="Brain" post="Behav Immun. (2020). [Epub ahead of print]. 10.1016/j.bbi.2020.05.074.32497776 152.GallowayJBNortonSBarkerRDBrookesACareyIClarkeBDet"/>
  <result pre="study. J Infect. (2020). [Epub ahead of print]. 10.1016/j.jinf.2020.05.064. 153.BandiSNevidMZMahdaviniaM." exact="African" post="American children are at higher risk for COVID-19 infection."/>
  <result pre="J Infect. (2020). [Epub ahead of print]. 10.1016/j.jinf.2020.05.064. 153.BandiSNevidMZMahdaviniaM. African" exact="American" post="children are at higher risk for COVID-19 infection. Pediatr"/>
  <result pre="10.1056/NEJMsa2011686.32459916 155.LinMTsengHKTrejautJALeeHLLooJHChuCCet al.. Association of HLA class I with severe" exact="acute" post="respiratory syndrome coronavirus infection. BMC Med Genet. (2003) 4:9."/>
  <result pre="155.LinMTsengHKTrejautJALeeHLLooJHChuCCet al.. Association of HLA class I with severe acute" exact="respiratory" post="syndrome coronavirus infection. BMC Med Genet. (2003) 4:9. 10.1186/1471-2350-4-912969506"/>
  <result pre="al.. Association of HLA class I with severe acute respiratory" exact="syndrome" post="coronavirus infection. BMC Med Genet. (2003) 4:9. 10.1186/1471-2350-4-912969506 156.LauYLPeirisJSPathogenesis"/>
  <result pre="infection. BMC Med Genet. (2003) 4:9. 10.1186/1471-2350-4-912969506 156.LauYLPeirisJSPathogenesis of severe" exact="acute" post="respiratory syndrome. Curr Opin Immunol. (2005) 17:404â€&quot;10. 10.1016/j.coi.2005.05.00915950449 157.NgMHLauKMLiLChengSHChanWYHuiPKet"/>
  <result pre="BMC Med Genet. (2003) 4:9. 10.1186/1471-2350-4-912969506 156.LauYLPeirisJSPathogenesis of severe acute" exact="respiratory" post="syndrome. Curr Opin Immunol. (2005) 17:404â€&quot;10. 10.1016/j.coi.2005.05.00915950449 157.NgMHLauKMLiLChengSHChanWYHuiPKet al.."/>
  <result pre="genotypes with susceptibility and resistance to the development of severe" exact="acute" post="respiratory syndrome. J Infect Dis. (2004) 190:515â€&quot;8. 10.1086/42152315243926 158.ShiYWangYShaoCHuangJGanJHuangXet"/>
  <result pre="with susceptibility and resistance to the development of severe acute" exact="respiratory" post="syndrome. J Infect Dis. (2004) 190:515â€&quot;8. 10.1086/42152315243926 158.ShiYWangYShaoCHuangJGanJHuangXet al.."/>
  <result pre="Death Differ. (2020) 27:1451â€&quot;4. 10.1038/s41418-020-0530-332205856 159.ZhaoJYangYHuangHLiDGuDLuXet al.Relationship between the ABO" exact="Blood" post="Group and the COVID-19 susceptibility. medRxiv. (2020). [Epub ahead"/>
  <result pre="ahead of print]. 10.1101/2020.03.11.20031096. 160.ChengYChengGChuiCHLauFYChanPKNgMHet al.. ABO blood group and" exact="susceptibility to" post="severe acute respiratory syndrome. JAMA. (2005) 293:1450â€&quot;1. 10.1001/jama.293.12.1450-c15784866 161.BalagopalAThomasDLThioCL."/>
  <result pre="10.1101/2020.03.11.20031096. 160.ChengYChengGChuiCHLauFYChanPKNgMHet al.. ABO blood group and susceptibility to severe" exact="acute" post="respiratory syndrome. JAMA. (2005) 293:1450â€&quot;1. 10.1001/jama.293.12.1450-c15784866 161.BalagopalAThomasDLThioCL. IL28B and"/>
  <result pre="160.ChengYChengGChuiCHLauFYChanPKNgMHet al.. ABO blood group and susceptibility to severe acute" exact="respiratory" post="syndrome. JAMA. (2005) 293:1450â€&quot;1. 10.1001/jama.293.12.1450-c15784866 161.BalagopalAThomasDLThioCL. IL28B and the"/>
  <result pre="JAMA. (2005) 293:1450â€&quot;1. 10.1001/jama.293.12.1450-c15784866 161.BalagopalAThomasDLThioCL. IL28B and the control of" exact="hepatitis C" post="virus infection. Gastroenterology. (2010) 139:1865â€&quot;76. 10.1053/j.gastro.2010.10.00420950615 162.WilliamsFMKFreidinMBManginoMCouvreurSViscontiABowyerRCEet al.Self-reported symptoms"/>
  <result pre="293:1450â€&quot;1. 10.1001/jama.293.12.1450-c15784866 161.BalagopalAThomasDLThioCL. IL28B and the control of hepatitis C" exact="virus infection." post="Gastroenterology. (2010) 139:1865â€&quot;76. 10.1053/j.gastro.2010.10.00420950615 162.WilliamsFMKFreidinMBManginoMCouvreurSViscontiABowyerRCEet al.Self-reported symptoms of covid-19"/>
  <result pre="mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset" exact="familial" post="HLH. Blood. (2011) 118:5794â€&quot;8. 10.1182/blood-2011-07-37014821881043 165.HeegMAmmannSKlemannCPanningMFalconeVHengelHet al.. Is an"/>
  <result pre="familial HLH. Blood. (2011) 118:5794â€&quot;8. 10.1182/blood-2011-07-37014821881043 165.HeegMAmmannSKlemannCPanningMFalconeVHengelHet al.. Is an" exact="infectious" post="trigger always required for primary hemophagocytic lymphohistiocytosis? lessons from"/>
  <result pre="10.1182/blood-2011-07-37014821881043 165.HeegMAmmannSKlemannCPanningMFalconeVHengelHet al.. Is an infectious trigger always required for" exact="primary" post="hemophagocytic lymphohistiocytosis? lessons from in utero and neonatal disease."/>
  <result pre="165.HeegMAmmannSKlemannCPanningMFalconeVHengelHet al.. Is an infectious trigger always required for primary" exact="hemophagocytic lymphohistiocytosis?" post="lessons from in utero and neonatal disease. Pediatr Blood"/>
  <result pre="required for primary hemophagocytic lymphohistiocytosis? lessons from in utero and" exact="neonatal" post="disease. Pediatr Blood Cancer. (2018) 65:e27344. 10.1002/pbc.2734430070073 166.HuangYPaxtonWAWolinskySMNeumannAUZhangLHeTet al.."/>
  <result pre="hemophagocytic lymphohistiocytosis? lessons from in utero and neonatal disease. Pediatr" exact="Blood" post="Cancer. (2018) 65:e27344. 10.1002/pbc.2734430070073 166.HuangYPaxtonWAWolinskySMNeumannAUZhangLHeTet al.. The role of"/>
  <result pre="role of a mutant CCR5 allele in HIV-1 transmission and" exact="disease" post="progression. Nat Med. (1996) 2:1240â€&quot;3. 10.1038/nm1196-12408898752 167.StawiskiEWDiwanjiDSuryamohanKGuptaRFellouseFASathirapongsasutiJFet al.Human ACE2"/>
  <result pre="Aging. (2020). [Epub ahead of print]. 10.18632/aging.103415.32501810 169.collab: (FDA) USFDACorona" exact="Virus Disease" post="2019. (COVID-19) (2020). Available online at: https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19 (accessed April"/>
  <result pre="(2020). [Epub ahead of print]. 10.18632/aging.103415.32501810 169.collab: (FDA) USFDACorona Virus" exact="Disease" post="2019. (COVID-19) (2020). Available online at: https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19 (accessed April"/>
  <result pre="Available online at: https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19 (accessed April 10, 2020). 170.collab: EMACoronavirus" exact="Disease" post="(COVID-19). (2020). Available online at: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19 (accessed April 10,"/>
  <result pre="(2020) 64:e00483â€&quot;20. 10.1128/AAC.00483-2032205349 173.MartinezMA. Compounds with therapeutic potential against novel" exact="respiratory" post="2019 coronavirus. Antimicrob Agents Chemother. (2020) 64:e00399â€&quot;20. 10.1128/AAC.00399-2032152082 174.GordonCJTchesnokovEPFengJYPorterDPGotteM."/>
  <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirus. J Biol Chem. (2020) 295: 4773â€&quot;9. 10.1074/jbc.AC120.01305632094225"/>
  <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirus. J Biol Chem. (2020) 295: 4773â€&quot;9. 10.1074/jbc.AC120.01305632094225 175.WangMCaoRZhangLYangXLiuJXuMet"/>
  <result pre="(2020). 10.1056/NEJMoa2015301 183.AntinoriSCossuMVRidolfoALRechRBonazzettiCPaganiGet al.. Compassionate remdesivir treatment of severe Covid-19" exact="pneumonia" post="in intensive care unit (ICU) and Non-ICU patients: Clinical"/>
  <result pre="optimized dosing design of hydroxychloroquine for the treatment of severe" exact="acute" post="respiratory syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. (2020)."/>
  <result pre="dosing design of hydroxychloroquine for the treatment of severe acute" exact="respiratory" post="syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. (2020). [Epub"/>
  <result pre="design of hydroxychloroquine for the treatment of severe acute respiratory" exact="syndrome" post="Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. (2020). [Epub ahead"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitro. Cell Discov. (2020) 6:16. 10.1038/s41421-020-0156-032194981 188.CaoBWangYWenDLiuWWangJFanGet al.."/>
  <result pre="chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical"/>
  <result pre="diphosphate as adjunctive therapy for patients hospitalized with severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial."/>
  <result pre="as adjunctive therapy for patients hospitalized with severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA"/>
  <result pre="190.MahevasMTranVTRoumierMChabrolAPauleRGuillaudCet al.. Clinical efficacy of hydroxychloroquine in patients with covid-19" exact="pneumonia" post="who require oxygen: observational comparative study using routine care"/>
  <result pre="the pharmacokinetics, safety, and efficacy of NI-03 in patients with" exact="chronic" post="pancreatitis: study protocol for a randomized controlled trial on"/>
  <result pre="randomized controlled trial on the assessment of camostat treatment in" exact="chronic" post="pancreatitis (TACTIC). Trials. (2019) 20:501. 10.1186/s13063-019-3606-y31412955 202.collab: Clinicaltrials.govThe Impact"/>
  <result pre="controlled trial on the assessment of camostat treatment in chronic" exact="pancreatitis" post="(TACTIC). Trials. (2019) 20:501. 10.1186/s13063-019-3606-y31412955 202.collab: Clinicaltrials.govThe Impact of"/>
  <result pre="20:501. 10.1186/s13063-019-3606-y31412955 202.collab: Clinicaltrials.govThe Impact of Camostat Mesilate on COVID-19" exact="Infection" post="(CamoCO-19). NCT04321096: Clinicaltrials.gov; (2020). Available online at: https://clinicaltrials.gov/ct2/show/NCT04321096?term=Camostat+mesylate&amp;amp;draw=2&amp;amp;rank=1 (accessed"/>
  <result pre="2020). 203.ToniatiPPivaSCattaliniMGarrafaERegolaFCastelliFet al.. Tocilizumab for the treatment of severe COVID-19" exact="pneumonia" post="with hyperinflammatory syndrome and acute respiratory failure: A single"/>
  <result pre="Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory" exact="syndrome" post="and acute respiratory failure: A single center study of"/>
  <result pre="the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and" exact="acute" post="respiratory failure: A single center study of 100 patients"/>
  <result pre="treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute" exact="respiratory" post="failure: A single center study of 100 patients in"/>
  <result pre="al.. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19," exact="acute" post="respiratory distress syndrome, and hyperinflammation: a retrospective cohort study."/>
  <result pre="Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute" exact="respiratory" post="distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet"/>
  <result pre="MastQMarkouNTheodorakopoulouMKomnosAMouktaroudiMet al.. Favorable anakinra responses in severe Covid-19 patients with" exact="secondary" post="hemophagocytic lymphohistiocytosis. Cell Host Microbe. (2020). [Epub ahead of"/>
  <result pre="al.. Favorable anakinra responses in severe Covid-19 patients with secondary" exact="hemophagocytic lymphohistiocytosis." post="Cell Host Microbe. (2020). [Epub ahead of print]. 10.1016/j.chom.2020.05.007.32411313"/>
  <result pre="ahead of print]. 10.1016/j.chom.2020.05.007.32411313 208.RilingerJKernWVDuerschmiedDSupadyABodeCStaudacherDLet al.. A prospective, randomised, double" exact="blind" post="placebo-controlled trial to evaluate the efficacy and safety of"/>
  <result pre="efficacy and safety of tocilizumab in patients with severe COVID-19" exact="pneumonia" post="(TOC-COVID): A structured summary of a study protocol for"/>
 </snippets>
</snippetsTree>
